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Letter to the Editor
We feel th at Alexander S. Young's recent a r t icle, "T he neurolept ic t rea tm ent of schizo-
phre nia: dosing strategi es, d epot pr eparations and novel m edi cation s" ijournal, 13, 18- 26),
may overs tat e t he r isks a nd com plica tions associat ed with t he use of c1ozapine. While
pre-marketing data (as cite d in the pa ckage insert) I did sugges t th at cloza pine had a relative ly
high incid en ce of se rious adverse effect s, post-marketing surve illa nce by the C loza ri l Pa t ient
Monitoring Se rvice (C PMS) does not confirm this. It would be un for tunat e if you r readers were
left with th e impression that th e usc of cloza pine were mor e di fficult or dangerous than it
truly is.
Young describes th e risk of ag ranu locytos is as 1%, with a death rat e of 0.05%. Based on
data collec te d by the C PMS on 99,502 patients to th e end of 1994, a more up-to-da te figure
would be 0.38%, with a tot al of 12 ag ra nulocytos is-rel a te d deaths (or 0.01%) in th e United
Sta tes "; this com pa res favor ably to th e ag ranulocytosis rat es of up to 0.7% which have been
obse rved with ph en ot hiazin es'' and, give n t he required wee kly hematological monitoring, may
well res ult in a lowerdeath rat e from blood dyscrasias t ha n is see n with typ ica l neuroleptics.
The risk of c1ozapine -associa te d se izu res a lso appears now to be sig nifica ntly less than
sugges te d by th e St age III s tud ies. Again, post-marketing surve illa nce via th e C PMS sugg ests a
se izure rate of 1.3% in the U nite d Stat es;" of th ese patients, half were conc urre n tly receivin g
medi cations known to lower th e se izu re threshold and a third had a pri or hist or y of se izures.
Only 0.4% of patients had recurrent se izures-t he o t he rs were isolat ed sing le event s during
init ia l dose titration-and three-quart ers of th ose pat ients were able to co ntinu e ta king
clozapine with the add itio n of an an ti-convulsa nt. In addit ion, seizure rates appear to be
co ns ide rably lower in Europ e, with only one se izure report ed in 765 patients t reated by th e
Munich group,' ·6 a nd sim ila r data from ot he r ce n te rsr /-" this may refl ect th e lower (but
see mingly equally efficac ious) dosages of clozapine used th ere.H•9 These figures again co mpare
favorab ly wi th t he 0.5-1% incid ence of se izu res as socia te d wit h typi cal neurolcpt ics. !"
Whi le we agree th at respirat ory a rres t is a n ex t re mely rare, but recognized, adve rse effect
associat ed with cloza pine us c, we would di sagree wit h the recom mendation th a t " pa t ien ts
sho uld not be on ben zodi az epines wh en starti ng cloza pine ." It is ce rtai nly tru e that this
co mbina t ion ca n ca use ext re me se da t ion (to th e point of obtu ndation), pa rt icularly in t he ea rly
s tages of cloza pine dose titration. II However, of th e six reported cases of respira tory arrest
assoc ia te d wit h t he com bina t ion, four pa t ien ts were on extre me ly high doses of or al ben zodi az-
epines (up to 32 mg/d ay lora zepam equiva lents ) and were started on conside ra bly high er doses
of cloza pine th an re commended by th e m a n ufact urer.F whi le th e other cases l3.14 rep or ted
pat ients on lon g-sta nding clozapine t herapy wh o were ad minis tered intraoenous benzod iaz-
epines, a rout e whi ch is well-r ecognized as producing a n id iosyncr atic, non-dose-dependent
respiratory a rre st in susce ptible persons. I> Alt ho ugh th e manufacturer's dat a sheet I urges
cau tion in the concomita nt pr escr ip tion of cloza pine and benzo diazepines, thi s regim en is no t
cont ra- indica te d .
T he use of clozapine does requ ire spe cia l precaution s a nd incr eased vigilance, but it would
be unfortunat e if pat ients suffe ring fro m a painful , terrifying a nd devastati ng disease were
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deni ed a sa fe, cos t-effective, well-t oler a ted and uniqu ely efficacious tr eatment becau se of
excessive conce rn about possibl e adverse effects on th e part of psychi a trists.
J ames Longh urst , MD
PGY-II in psychiatry, Yale University
J oseph Cassar, MD
PGY-II
Carl Young, MD
Psychoph armacology Fellow
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